-
噬菌体展示技术是一项将外源的重组肽、蛋白质包括抗体片段融合到噬菌体颗粒衣壳蛋白上, 用于筛选功能性多肽或蛋白片段的生物技术。Smith将外源基因插入丝状噬菌体f1的P3基因, 获得的重组噬菌体可在体外稳定增生, 使目的基因编码的多肽以融合蛋白的形式展示在噬菌体表面, 从而创立了噬菌体展示技术[1]。此方法可在受体分子尚不清楚的情况下, 利用多肽片段特异性与噬菌体表面蛋白结合的特点, 寻找特异性结合的靶标分子, 确定其结合部位和结构域[2-3]。噬菌体展示技术能大大缩短研究周期, 而且筛选过程可以与治疗在相同条件下进行, 避免了体外筛选得到的多肽片段在体内实验无效或活性低的缺点, 保证了筛选到的短肽的靶向特异性。
利用噬菌体展示技术筛选的多肽和抗体由于分子小、穿透力强、亲和力和特异性高等特点, 适用于肿瘤三维成像和分子影像学诊断, 可以用于肿瘤的免疫放射治疗及其定位诊断、疗效评价和制定后续治疗方案。
噬菌体展示技术在分子核医学中的应用
Application of phage display technique in molecular nuclear medicine
-
摘要: 噬菌体展示技术是研究分子间多种作用的技术, 它能够在机理尚未明确的情况下研究蛋白质与蛋白质、蛋白质与多肽、蛋白质与核酸的相互作用, 这种技术的一个关键优势是, 它可以研究分子间的直接联系, 得到不同亲和力的分子, 一次性实现高效筛选多肽的目的。近年来随着噬菌体展示技术的成熟, 该技术被广泛应用于生命科学研究的不同领域, 如:单克隆抗体制备、多肽筛选、疫苗研制、基因治疗及细胞信号转导研究等。该文综述了噬菌体展示技术在分子核医学相关研究中的运用。Abstract: Phage display is a molecular diversity technology that allows the presentation of large peptide and protein libraries on the surface of filamentous phage. Phage display libraries permit the selection of peptides and proteins, including antibodies, with high affinity and specificity for almost any target. In recent years, along with phage display technology maturated, it has been widely used in screening tumor antibody library, the preparation of monoclonal antibody, polypeptide, drug design, gene therapy and cell signal transduction. This review serves as an introduction to phage display in molecular nuclear medicine, and recent application in display technology.
-
Key words:
- Radionuclide imaging /
- Radioactive tracers /
- Phage display
-
[1] Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science, 1985, 228(4705): 1315-1317. [2] Bazan J, Całkosiński I, Gamian A. Phage display-a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother, 2012, 8(12): 1817-1828. [3] Castel G, Chtéoui M, Heyd B, et al. Phage display of combinatorial peptide libraries: application to antiviral research. Molecules, 2011, 16(5): 3499-3518. [4] Jurisson SS, Lydon JD. Potential technetium small molecule radiopharmaceuticals. Chem Rev, 1999, 99(9): 2205-2207. [5] Bourguignon MH, Loc'h G, Mazière B. The future of SPECT radioisotopes: technetium-99m or iodine-123?. J Nucl Biol Med, 1994, 38(4): 573-576. [6] Cutler SJ, Perez KL, Barnhart HX, et al. Observer detection limits for a dedicated SPECT breast imaging system. Phys Med Biol, 2010, 55(7): 1903-1916. [7] Chen L, Wang Y, Cheng D, et al. Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents. Nucl Med Commun, 2011, 32(10): 920-924. [8] Rusckowski M, Gupta S, Liu G, et al. Evidence of specificity of radiolabeled phage display peptides for the TAG-72 antigen. Cancer Biother Radiopharm, 2007, 22(4): 564-572. [9] Hui X, Han Y, Liang S, et al. Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. J Control Release, 2008, 131(2): 86-93. [10] 兰晓莉, 高再荣, 孙琳, 等.核素标记血管多肽显像诊断恶性肿瘤实验研究.肿瘤学杂志, 2008, 14(8): 627-630.
[11] Bakker WH, Krenning EP, Reubi JC, et al. In vivo application of 111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci, 1991, 49(22): 1593-1601. [12] Anderson CJ, Welch MJ. Radiometal-labeled agents(non-technetium) for diagnostic imaging. Chem Rev, 1999, 99(9): 2219-2234. [13] Boswell CA, Mundo EE, Zhang C, et al. Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med, 2012, 53(9): 1454-1461. [14] Zou J, Glinsky VV, Landon LA, et al. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis, 2005, 26(2): 309-318. [15] Kumar SR, Deutscher SL. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors. J Nucl Med, 2008, 49(5): 796-803. [16] Hooker SD, Freeman LH, Stewart P. Pet therapy research: a historical review. Holist Nurs Pract, 2002, 16(5): 17-23. [17] Champion L, Brain E, Giraudet AL, et al. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer, 2011, 117(8): 1621-1629. [18] Picchio M, Giovannini E, Crivellaro C, et al. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiother Oncol, 2010, 96(3): 347-350. [19] SUN L, CHU T, WANG Y, et al. Radiolabeling and biodistribution of a nasopharyngeal carcinoma-targeting peptide identified by in vivo phage display. Acta Biochim Biophys Sin(Shanghai), 2007, 39(8): 624-632. [20] Zitzmann S, Mier W, Schad A, et al. A new prostate carcinoma binding peptide(DUP-1)for tumor imaging and therapy. Clin Cancer Res, 2005, 11(1): 139-146. [21] Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic maligna-ncies. Semin Nucl Med, 2002, 32(2): 123-132. [22] Mitra A, Nan A, Papadimitriou JC, et al. Polymer-peptide conjuga-tes for angiogenesis targeted tumor radiotherapy. Nucl Med Biol, 2006, 33(1): 43-52. [23] Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging, 2002, 29(7): 855-862. [24] Paganelli G, Bodei L, Handkiewicz Junak D, et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers, 2002, 66(6): 393-398. [25] Zitzmann S, Krämer S, Mier W, et al. Identification and evaluation of a new tumor cell-binding peptide, FROP-1. J Nucl Med, 2007, 48(6): 965-972.
计量
- 文章访问数: 1825
- HTML全文浏览量: 1195
- PDF下载量: 2